USE OF OMEPRAZOLE AS A PROBE DRUG FOR CYP2C19 PHENOTYPE IN SWEDISH CAUCASIANS: COMPARISON WITH S-MEPHENYTOIN HYDROXY-LATION PHENOTYPE AND CYP2C19 GENOTYPE

CHANG, M., DAHL, M.L., TYBRING, G., GOTHARSON, E., & BERTILSSON, L.. (1995). USE OF OMEPRAZOLE AS A PROBE DRUG FOR CYP2C19 PHENOTYPE IN SWEDISH CAUCASIANS: COMPARISON WITH S-MEPHENYTOIN HYDROXY-LATION PHENOTYPE AND CYP2C19 GENOTYPE. PHARMACOGENETICS AND GENOMICS, 5(-), 358-363. SID. https://sid.ir/paper/553183/en

CHANG M., DAHL M.L., TYBRING G., GOTHARSON E., BERTILSSON L.. USE OF OMEPRAZOLE AS A PROBE DRUG FOR CYP2C19 PHENOTYPE IN SWEDISH CAUCASIANS: COMPARISON WITH S-MEPHENYTOIN HYDROXY-LATION PHENOTYPE AND CYP2C19 GENOTYPE. PHARMACOGENETICS AND GENOMICS[Internet]. 1995;5(-):358-363. Available from: https://sid.ir/paper/553183/en

M. CHANG, M.L. DAHL, G. TYBRING, E. GOTHARSON, and L. BERTILSSON, “USE OF OMEPRAZOLE AS A PROBE DRUG FOR CYP2C19 PHENOTYPE IN SWEDISH CAUCASIANS: COMPARISON WITH S-MEPHENYTOIN HYDROXY-LATION PHENOTYPE AND CYP2C19 GENOTYPE,” PHARMACOGENETICS AND GENOMICS, vol. 5, no. -, pp. 358–363, 1995, [Online]. Available: https://sid.ir/paper/553183/en